Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
View: Text | PDF
Research Article Pulmonology

Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease

  • Text
  • PDF
Abstract

Wilms’ tumor 1 (WT1) is a critical transcriptional regulator of mesothelial cells during lung development but is downregulated in postnatal stages and adult lungs. We recently showed that WT1 is upregulated in both mesothelial cells and mesenchymal cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal fibrotic lung disease. Although WT1-positive cell accumulation leading to severe fibrotic lung disease has been studied, the role of WT1 in fibroblast activation and pulmonary fibrosis remains elusive. Here, we show that WT1 functions as a positive regulator of fibroblast activation, including fibroproliferation, myofibroblast transformation, and extracellular matrix (ECM) production. Chromatin immunoprecipitation experiments indicate that WT1 binds directly to the promoter DNA sequence of α-smooth muscle actin (αSMA) to induce myofibroblast transformation. In support, the genetic lineage tracing identifies WT1 as a key driver of mesothelial-to-myofibroblast and fibroblast-to-myofibroblast transformation. Importantly, the partial loss of WT1 was sufficient to attenuate myofibroblast accumulation and pulmonary fibrosis in vivo. Further, our coculture studies show that WT1 upregulation leads to non–cell autonomous effects on neighboring cells. Thus, our data uncovered a pathogenic role of WT1 in IPF by promoting fibroblast activation in the peripheral areas of the lung and as a target for therapeutic intervention.

Authors

Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala

×

Figure 1

Postnatal WT1-positive mesothelial cell contributions to myofibroblasts in pulmonary fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Postnatal WT1-positive mesothelial cell contributions to myofibroblasts ...
(A) The dramatic decrease in the expression of WT1 in developing mouse lung at E14.5 and expression levels were normalized to HPRT mRNA (n = 3–5/gestational age). Data are presented as mean ± SEM. Statistical significance was calculated using 1-way ANOVA with Sidak’s multiple comparison for multiple comparisons. **P < 0.005, ***P < 0.0005. (B) Immunostaining shows the presence of WT1 protein in mesothelial cells (pleural surface) that coexpress calretinin (red) but not in myofibroblasts (green) of αSMAYFP mice embryos at E15.5. Scale bar: 50 μm. (C) WT1 staining (white) is detected in a subset of mesothelial cells positive for calretinin (red) in WT mice embryos at E15.5. Scale bar: 50 μm. (D) Schematic diagram of treatments with tamoxifen and Dox. Control or TGFα/WT1CreERT2/mTmG mice were induced with tamoxifen, and 1 week later, pulmonary fibrosis was induced by administering Dox in food for 4 or 6 weeks. (E) Immunofluorescence images show progressive accumulation of WT1-derived cells residing in subpleura but not adventitia in TGFα/WT1CreERT2/mTmG mice compared with control WT1CreERT2/mTmG mice on Dox for 4 or 6 weeks. Scale bar: 50 μm. (F) Immunostaining shows the presence of αSMA protein in WT1-positive mesothelium-derived mesenchymal cells of TGFα/WT1CreERT2/mTmG mice on Dox for 4 weeks. Note the presence of 2 distinct mesenchymal cells in subpleural fibrotic lesions that are marked by αSMA protein in GFP-positive cells (WT1-positive mesothelial cells) and GFP-negative (WT1-positive mesenchymal cells) cells. Scale bar: 50 μm.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts